Dynavax Announces Collaboration with the University of Queensland and the Coalition for Epidemic Preparedness (CEPI) Focused ...
March 02 2020 - 8:00AM
Dynavax Technologies Corporation (NASDAQ: DVAX), a
biopharmaceutical company focused on developing and commercializing
novel vaccines, today announced it is collaborating with the
University of Queensland (UQ) as part of a Coalition for Epidemic
Preparedness (CEPI) initiative to develop a vaccine to prevent
COVID-19. Dynavax is providing technical expertise and the
Company’s proprietary toll-like receptor 9 (TLR9) agonist adjuvant,
CpG 1018, to support this initiative.
CpG 1018 is the adjuvant used in HEPLISAV-B®
[Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis
B vaccine approved by the U.S. Food and Drug Administration (FDA).
Dynavax developed CpG 1018 to provide an increased vaccine immune
response, which has been demonstrated in HEPLISAV-B. CpG 1018
provides a well‑developed technology and a significant safety
database, potentially accelerating the development of a COVID-19
vaccine.
CEPI, in conjunction with the World Health
Organization, is leading multiple programs/partnerships that seek
to improve the scientific understanding of the novel coronavirus,
and to develop vaccines against it. UQ and CEPI established a
partnership in January 2019 focused on developing a “molecular
clamp” vaccine platform, a technology that enables targeted and
rapid vaccine production against multiple viral pathogens.
Building on this existing partnership, CEPI requested UQ use its
recently developed rapid response technology, which allows for the
rapid generation of new vaccines from the knowledge of a virus’s
genetic sequence information, to develop a new vaccine against
COVID-19.
“The comprehensive humanitarian response to
address the risk of COVID-19 by the vaccine development community
is a testament to the dedication our industry has to global public
health,” commented Ryan Spencer, Chief Executive Officer of
Dynavax. “We are proud to contribute to this global effort to
develop a vaccine to prevent COVID-19 in collaboration with the
exceptional team of researchers at the University of
Queensland.”
About DynavaxDynavax is a
commercial stage biopharmaceutical company developing and
commercializing novel vaccines. The Company launched its first
commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant),
Adjuvanted], in February 2018, following U.S. FDA approval for
prevention of infection caused by all known subtypes of hepatitis B
virus in adults age 18 years and older. For more information,
visit www.dynavax.com and follow the company on LinkedIn.
About University of
QueenslandThe University of Queensland is one of
Australia’s leading research and teaching institutions, a global
top 50 university, ranked first in Australia and ninth in the world
for biotechnology. www.uq.edu.au.
About Coalition for Epidemic
Preparedness Innovations (CEPI)CEPI is an innovative
partnership between public, private, philanthropic, and civil
organisations, launched at Davos in 2017, to develop vaccines to
stop future epidemics. CEPI has reached over US$750 million of its
$1 billion funding target. CEPI’s priority diseases include Ebola
virus, Lassa virus, Middle East Respiratory Syndrome coronavirus,
Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also
invests in platform technologies that can be used for rapid vaccine
and immunoprophylactic development against unknown pathogens (ie,
Disease X). To date, CEPI has committed to investing over $475
million in vaccine and platform development. Learn more at
cepi.net. Follow us at @CEPIvaccines.
Forward-Looking StatementsThis
press release contains "forward-looking" statements, including
statements regarding the potential to develop a COVID-19 vaccine
and to do so on an accelerated basis. Actual results may
differ materially from those set forth in this press release due to
the risks and uncertainties inherent in vaccine research and
development, including the timing of completing development, the
results of clinical trials, and whether and when the vaccine will
be approved for use, as well as other risks detailed in the "Risk
Factors" section of our Annual Report on Form 10-K for the fiscal
year ended December 31, 2018, as well as discussions of potential
risks, uncertainties and other important factors in our other
filings with the U.S. Securities and Exchange Commission. We
undertake no obligation to revise or update information herein to
reflect events or circumstances in the future, even if new
information becomes available. Information on Dynavax's website at
www.dynavax.com is not incorporated by reference in our current
periodic reports with the SEC.
Contacts:Nicole Arndt, Senior Manager, Investor
Relationsnarndt@dynavax.com510-665-7264
Derek Cole, President Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Sep 2023 to Sep 2024